Key result
ANGPTL3 inhibition significantly reduces LDL-C and triglyceride levels, representing an innovative therapeutic approach for severe dyslipidemia such as homozygous familial hypercholesterolemia.
Why the study?
ANGPTL3 plays a central role in lipid metabolism and is a promising therapeutic target for managing refractory dyslipidemia and high cardiovascular risk.
Does ANGPTL3 inhibition reduce LDL-C and triglyceride levels in patients with dyslipidemia?
Does ANGPTL3 inhibition reduce LDL-C and triglyceride levels in patients with dyslipidemia?
ANGPTL3 inhibition represents a promising therapeutic approach for managing severe and refractory dyslipidemias by significantly reducing LDL-C and triglyceride levels.
May support ANGPTL3 inhibition for refractory dyslipidemia; leaves open need for randomized outcome trials before practice change.
The ANGPTL3 protein plays a central role in lipid metabolism, regulating triglyceride (TG) and LDL-C levels, and is a promising therapeutic target for the management of refractory dyslipidemia and high cardiovascular risk.This study reviewed the literature on the mechanisms of action of ANGPTL3 and advances in therapies based on its inhibition, including agents such as evinacumab, antisense oligonucleotides (ASOs) and emerging technologies such as gene editing.Thirty articles published between 2020 and 2024 in PubMed were selected.The results indicate that ANGPTL3 inhibition significantly reduces LDL-C and TG levels, promoting benefits in high-risk populations, such as patients with homozygous familial hypercholesterolemia (HoFH).In addition, ANGPTL3-targeted vaccines and RNA-based therapies show promise in lipid modulation and cardiovascular risk reduction.However, challenges such as accessibility, high cost and lack of longitudinal studies limit their implementation on a large scale.It is concluded that ANGPTL3 inhibition represents an innovative and effective therapeutic approach with the potential to transform the management of severe dyslipidemia and reduce the burden of cardiovascular disease.Future studies should focus on cost-effective strategies, long-term validation and personalization of interventions, promoting greater accessibility and clinical impact.
No takes yet. Share an insight, caveat, or question.
Vieira et al. (2025) conducted a review in Dyslipidemia. ANGPTL3 inhibition was evaluated on Lipid levels (LDL-C and triglycerides). ANGPTL3 inhibition significantly reduces LDL-C and triglyceride levels, representing an innovative therapeutic approach for severe dyslipidemia such as homozygous familial hypercholesterolemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: